This article is more than 5 years old. Information may no longer be current.

Late-breaking trials, first report investigations announced for TCT

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Cardiovascular Research Foundation has announced the lineup for the late-breaking trials and first report investigations for this year’s Transcathether Cardiovascular Therapeutics Scientific Symposium.

The meeting, which will take place from Sept. 13 to 17 in Washington, D.C., will highlight a wide range of device- and pharmaceutical-based advancements in the field of interventional cardiology.

The first day of plenary sessions on Sept. 13 will feature the results of several trials assessing transcatheter aortic valve replacement. Among them are the 5-year results of the PARTNER I trial, which examined TAVR with the Sapien valve (Edwards Lifesciences) vs. conservative care in high-risk patients with aortic stenosis; and a cost-effectiveness analysis of the CoreValve High Risk trial that looked at TAVR with the CoreValve (Medtronic) vs. surgical AVR in high-risk patients with aortic stenosis.

Other trials that will be presented during the 4 days of plenary sessions include:

• The prospective, randomized SECURITY trial testing 6-month vs. 12-month duration of dual antiplatelet therapy after drug-eluting stent implantation;
• The TRANSLATE-ACS large-scale registry evaluating patterns of use and 1-year outcomes with prasugrel (Effient, Daiichi Sankyo/Eli Lilly) vs. clopidogrel in patients with acute MI undergoing PCI;
• The prospective, randomized ABSORB II trial, comparing an everolimus-eluting bioresorbable scaffold with an everolimus-eluting stent in patients with CAD;
• The prospective, randomized, sham-controlled Symplicity Flex trial of renal sympathetic denervation in patients with refractory hypertension;
• The prospective, randomized OCT STEMI trial, which is examining optical coherence tomography guidance during primary PCI for acute MI;
• The prospective, randomized PRIMA trial assessing patent foramen ovale closure in patients with refractory migraine with aura;
• The prospective, randomized EXCITE ISR trial looking at excimer laser atherectomy vs. balloon angioplasty for femoropopliteal in-stent restenosis.

Stay tuned to Healio.com/Intervention for more news on TCT 2014 as it becomes available.